Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Untangling the role of mutant histone H3 in diffuse intrinsic pontine glioma

New studies advance the mechanistic understanding of mutant histone H3 in diffuse intrinsic pontine glioma (DIPG) and demonstrate two epigenetic approaches, BET inhibition and EZH2 inhibition, as potential therapeutic strategies for DIPG.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Epigenetic therapy for DIPG tumors.

Kim Caesar/Springer Nature

References

  1. Buczkowicz, P. & Hawkins, C. Front. Oncol. 5, 147 (2015).

    Article  Google Scholar 

  2. Schwartzentruber, J. et al. Nature 482, 226–231 (2012).

    Article  CAS  Google Scholar 

  3. Buczkowicz, P. et al. Nat. Genet. 46, 451–456 (2014).

    Article  CAS  Google Scholar 

  4. Wu, G. et al. Nat. Genet. 46, 444–450 (2014).

    Article  CAS  Google Scholar 

  5. Mohammad, F. et al. Nat. Med. 23, 483–492 (2017).

    Article  CAS  Google Scholar 

  6. Piunti, A. et al. Nat. Med. 23, 493–500 (2017).

    Article  CAS  Google Scholar 

  7. Kallappagoudar, S., Yadav, R.K., Lowe, B.R. & Partridge, J.F. Chromosoma 124, 177–189 (2015).

    Article  CAS  Google Scholar 

  8. Lewis, P.W. et al. Science 340, 857–861 (2013).

    Article  CAS  Google Scholar 

  9. Bender, S. et al. Cancer Cell 24, 660–672 (2013).

    Article  CAS  Google Scholar 

  10. Chan, K.M. et al. Genes Dev. 27, 985–990 (2013).

    Article  CAS  Google Scholar 

  11. Schroeder, K.M., Hoeman, C.M. & Becher, O.J. Pediatr. Res. 75, 205–209 (2013).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Caretha L Creasy.

Ethics declarations

Competing interests

C.L.C. is an employee and stock owner of GSK, a company with compounds in clinical development for both EZH2 and BET. The two articles that are summarized in the News & Views article indicate that treatment with inhibitors of EZH2 or BET may be an effective therapy for diffuse intrinsic pontine glioma.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Creasy, C. Untangling the role of mutant histone H3 in diffuse intrinsic pontine glioma. Nat Med 23, 413–414 (2017). https://doi.org/10.1038/nm.4320

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.4320

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer